Viewing Study NCT00213538



Ignite Creation Date: 2024-05-05 @ 12:02 PM
Last Modification Date: 2024-10-26 @ 9:18 AM
Study NCT ID: NCT00213538
Status: COMPLETED
Last Update Posted: 2017-06-14
First Post: 2005-09-13

Brief Title: Gene Expression Profiling in PBMCs as a Tool for Prediction of Anakinra Responsiveness in Rheumatoid Arthritis
Sponsor: University Hospital Rouen
Organization: University Hospital Rouen

Study Overview

Official Title: Gene Expression Profiling in PBMCs as a Tool for Prediction of Anakinra Responsiveness in Rheumatoid Arthritis
Status: COMPLETED
Status Verified Date: 2017-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The objective of the study is to identify and validate predictive markers of anakinra responsiveness in RA patients by a transcriptomic approach

Patients with active RA ACR criteria were given subcutaneous anakinra 100mgd 3 associated with metotrexate Anakinra efficacy was evaluated at week 12 using the EULAR response criteria

A blood sample was collected just before the onset of anakinra treatment and total RNAs were extracted from the peripheral blood mononuclear cells The 33P radiolabeled mRNAs were hybridized duplicate or triplicate over a set of 10000 human cDNA probes spotted at a high density on nylon membranes Data were normalized and filtered to allow the comparison between RNA samples Statistical analyses were performed with the R software and hierarchical clustering was performed with the Cluster and Tree View softwares
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None